For patients receiving lenvatinib therapy, the observed overall survival rates are 87.5% at 6 months, 71.4% at 12 months, and 57.1% at 18 months. These rates specifically apply to the treatment of poorly differentiated thyroid cancer.
Lenvatinib is an oral multi-kinase inhibitor approved for the treatment of various cancers, including differentiated thyroid cancer that is refractory to radioactive iodine. Its efficacy is evaluated by various metrics, with overall survival being a critical indicator of long-term patient outcomes.
Overall Survival Rates with Lenvatinib
The overall survival (OS) reflects the percentage of patients who are still alive at specific time points after starting treatment. For lenvatinib in the context of poorly differentiated thyroid cancer, the survival rates are as follows:
| Time Point | Overall Survival Rate |
|---|---|
| 6 Months | 87.5% |
| 12 Months | 71.4% |
| 18 Months | 57.1% |
It's important to note that the median overall survival for lenvatinib therapy in this context was not reached, indicating that more than half of the patients in the study were still alive at the end of the observation period, or their median survival extended beyond the study's follow-up duration.
Key Efficacy Outcomes of Lenvatinib Therapy
Beyond overall survival, other outcomes provide a comprehensive picture of lenvatinib's effectiveness:
- Median Progression-Free Survival (PFS): Patients treated with lenvatinib experienced a median progression-free survival of 12 months. PFS measures the length of time during and after the treatment that the patient lives without the disease getting worse.
- Response to Treatment:
- The median time until patients achieved their best overall response to lenvatinib therapy was 3 months. This highlights a relatively prompt effect of the medication.
- The median duration of response, meaning how long patients maintained their positive response to treatment, was 7.5 months.
These outcomes collectively demonstrate lenvatinib's role in managing and extending the lives of patients with challenging forms of thyroid cancer.
